Data as of Mar 14
| +0.10 / +2.73%|
The 4 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 2.00, with a high estimate of 4.00 and a low estimate of 1.50. The median estimate represents a -46.81% decrease from the last price of 3.76.
The current consensus among 8 polled investment analysts is to Hold stock in Corcept Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.